# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $112...
Bernstein analyst William Pickering upgrades Biomarin Pharmaceutical (NASDAQ:BMRN) from Market Perform to Outperform and rai...
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost red...
TD Cowen analyst Phil Nadeau maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $12...
Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price ...